{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:45:37Z","timestamp":1782866737617,"version":"3.54.5"},"reference-count":33,"publisher":"Elsevier BV","issue":"6-7","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:00:00Z","timestamp":1771804800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006400","name":"Alnylam Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006400","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archives of Cardiovascular Diseases"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.acvd.2025.11.014","type":"journal-article","created":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:28:40Z","timestamp":1770683320000},"page":"452-460","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of RNAi therapeutics on cardiac parameters in patients with hereditary transthyretin amyloidosis initially treated with stabilizers: A French real-world study"],"prefix":"10.1016","volume":"119","author":[{"given":"Antoine","family":"Fraix","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Algalarrondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Lairez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Arnal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Piriou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maud","family":"Michaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilbert","family":"Habib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Roubille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Lucas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine Jobb\u00e9","family":"Duval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9reng\u00e8re","family":"Bachelet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erwan","family":"Donal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thibaud","family":"Damy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"R\u00e9ant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mounira","family":"Kharoubi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Huttin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.acvd.2025.11.014_bib0005","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41582-019-0210-4","article-title":"Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease","volume":"15","author":"Adams","year":"2019","journal-title":"Nat Rev Neurol"},{"issue":"6","key":"10.1016\/j.acvd.2025.11.014_bib0010","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1136\/jnnp-2021-327909","article-title":"Novel approaches to diagnosis and management of hereditary transthyretin amyloidosis","volume":"93","author":"Carroll","year":"2022","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"10","key":"10.1016\/j.acvd.2025.11.014_bib0015","doi-asserted-by":"crossref","first-page":"3610","DOI":"10.1007\/s00415-020-09962-6","article-title":"Chance or challenge, spoilt for choice? New recommendations on diagnostic and therapeutic considerations in hereditary transthyretin amyloidosis with polyneuropathy: the German\/Austrian position and review of the literature","volume":"268","author":"Dohrn","year":"2021","journal-title":"J Neurol"},{"issue":"1","key":"10.1016\/j.acvd.2025.11.014_bib0020","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1161\/CIR.0000000000000792","article-title":"Cardiac amyloidosis: evolving diagnosis and management: a scientific statement from the American Heart Association","volume":"142","author":"Kittleson","year":"2020","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.acvd.2025.11.014_bib0025","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.acvd.2023.07.003","article-title":"Changes in amyloidosis phenotype over 11 years in a cardiac amyloidosis referral centre cohort in France","volume":"116","author":"Damy","year":"2023","journal-title":"Arch Cardiovasc Dis"},{"issue":"1","key":"10.1016\/j.acvd.2025.11.014_bib0030","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1186\/s13023-023-02933-w","article-title":"Incidence and survival of transthyretin amyloid cardiomyopathy from a French Nationwide Study of in- and out-patient databases","volume":"18","author":"Damy","year":"2023","journal-title":"Orphanet J Rare Dis"},{"issue":"6","key":"10.1016\/j.acvd.2025.11.014_bib0035","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.jacc.2005.05.073","article-title":"Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy","volume":"46","author":"Perugini","year":"2005","journal-title":"J Am Coll Cardiol"},{"issue":"24","key":"10.1016\/j.acvd.2025.11.014_bib0040","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy diagnosis of cardiac transthyretin amyloidosis","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.acvd.2025.11.014_bib0045","doi-asserted-by":"crossref","first-page":"471","DOI":"10.2174\/1570159X21666221108094736","article-title":"Drug and gene therapy for treating variant transthyretin amyloidosis (ATTRv) neuropathy","volume":"21","author":"Dardiotis","year":"2023","journal-title":"Curr Neuropharmacol"},{"key":"10.1016\/j.acvd.2025.11.014_bib0050","unstructured":"https:\/\/www.has-sante.fr\/upload\/docs\/evamed\/CT18579_VYNDAQEL_PIC_INS_AvisDef_CT18579.pdf."},{"key":"10.1016\/j.acvd.2025.11.014_bib0055","unstructured":"https:\/\/ansm.sante.fr\/actualites\/decision-du-17-05-2024-cadre-de-prescription-compassionnelle-de-onpattro-patisiran-2-mg-ml-solution-a-diluer-pour-perfusion."},{"issue":"10","key":"10.1016\/j.acvd.2025.11.014_bib0060","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1038\/s41569-022-00683-z","article-title":"RNA-targeting and gene editing therapies for transthyretin amyloidosis","volume":"19","author":"Aimo","year":"2022","journal-title":"Nat Rev Cardiol"},{"issue":"7","key":"10.1016\/j.acvd.2025.11.014_bib0065","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1007\/s00415-022-10978-3","article-title":"Clinical improvement after change of therapy from tafamidis to patisiran in progressive TTR amyloidosis post-liver transplantation","volume":"269","author":"Bulinski","year":"2022","journal-title":"J Neurol"},{"issue":"1","key":"10.1016\/j.acvd.2025.11.014_bib0070","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1080\/13506129.2019.1685487","article-title":"Inotersen therapy of transthyretin amyloid cardiomyopathy","volume":"27","author":"Dasgupta","year":"2020","journal-title":"Amyloid"},{"issue":"4","key":"10.1016\/j.acvd.2025.11.014_bib0075","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1161\/CIRCULATIONAHA.118.035831","article-title":"Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis","volume":"139","author":"Solomon","year":"2019","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.acvd.2025.11.014_bib0080","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1080\/13506129.2017.1374946","article-title":"Safety and efficacy of a TTR specific antisense oligonucleotide in patients with transthyretin amyloid cardiomyopathy","volume":"24","author":"Benson","year":"2017","journal-title":"Amyloid"},{"issue":"1","key":"10.1016\/j.acvd.2025.11.014_bib0085","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1080\/13506129.2022.2091985","article-title":"Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial","volume":"30","author":"Adams","year":"2023","journal-title":"Amyloid"},{"issue":"11","key":"10.1016\/j.acvd.2025.11.014_bib0090","doi-asserted-by":"crossref","first-page":"ytab415","DOI":"10.1093\/ehjcr\/ytab415","article-title":"Genome silencer therapy leading to regression of cardiac amyloid load on cardiovascular magnetic resonance: a case report","volume":"5","author":"Florian","year":"2021","journal-title":"Eur Heart J Case Rep"},{"issue":"4","key":"10.1016\/j.acvd.2025.11.014_bib0095","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1093\/qjmed\/hcae005","article-title":"siRNA therapy improves multimodality imaging in hereditary transthyretin cardiac amyloidosis: a case report","volume":"117","author":"Awaya","year":"2024","journal-title":"Qjm"},{"issue":"1","key":"10.1016\/j.acvd.2025.11.014_bib0100","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2409134","article-title":"Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy","volume":"392","author":"Fontana","year":"2025","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.acvd.2025.11.014_bib0105","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.jcmg.2016.05.007","article-title":"Early phase (99)Tc-HMDP scintigraphy for the diagnosis and typing of cardiac amyloidosis","volume":"10","author":"Galat","year":"2017","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.acvd.2025.11.014_bib0110","unstructured":"https:\/\/www.has-sante.fr\/jcms\/p_3351757\/fr\/neuropathie-amyloide-hereditaire-a-transthyretine-nah-ttr."},{"issue":"6","key":"10.1016\/j.acvd.2025.11.014_bib0115","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/ejhf.2198","article-title":"Expert consensus on the monitoring of transthyretin amyloid cardiomyopathy","volume":"23","author":"Garcia-Pavia","year":"2021","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"10.1016\/j.acvd.2025.11.014_bib0120","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.acvd.2024.10.323","article-title":"Management of conduction disease and arrhythmias in patients with cardiac amyloidosis: a position paper from the Working Group of Cardiac Pacing and Electrophysiology of the French Society of Cardiology","volume":"118","author":"Lellouche","year":"2025","journal-title":"Arch Cardiovasc Dis"},{"key":"10.1016\/j.acvd.2025.11.014_bib0125","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1186\/s13023-024-03401-9","article-title":"A series of cases of transthyretin amyloid cardiomyopathy with negative bone scintigraphy but a confirmed positive endomyocardial biopsy","volume":"19","author":"Fraix","year":"2024","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"10.1016\/j.acvd.2025.11.014_bib0130","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1080\/13506129.2022.2120799","article-title":"Functional and morphometric assessment of small-fibre damage in late-onset hereditary transthyretin amyloidosis with polyneuropathy: the controversial relation between small-fibre-related symptoms and diagnostic test findings","volume":"30","author":"Galosi","year":"2023","journal-title":"Amyloid"},{"issue":"6\u20137","key":"10.1016\/j.acvd.2025.11.014_bib0135","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.acvd.2025.03.121","article-title":"Underestimated vascular dysfunction is a critical feature of the impaired cardiovascular profile in patients with transthyretin amyloidosis","volume":"118","author":"Monfort","year":"2025","journal-title":"Arch Cardiovasc Dis"},{"issue":"1","key":"10.1016\/j.acvd.2025.11.014_bib0140","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.acvd.2025.11.014_bib0145","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/j.jacc.2023.12.036","article-title":"Stratifying disease progression in patients with cardiac ATTR amyloidosis","volume":"83","author":"Ioannou","year":"2024","journal-title":"J Am Coll Cardiol"},{"issue":"17","key":"10.1016\/j.acvd.2025.11.014_bib0150","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1056\/NEJMoa2300757","article-title":"Patisiran treatment in patients with transthyretin cardiac amyloidosis","volume":"389","author":"Maurer","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.acvd.2025.11.014_bib0155","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/ejhf.3138","article-title":"Impact of vutrisiran on exploratory cardiac parameters in hereditary transthyretin-mediated amyloidosis with polyneuropathy","volume":"2","author":"Garcia-Pavia","year":"2024","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"10.1016\/j.acvd.2025.11.014_bib0160","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.acvd.2024.08.006","article-title":"Clinical outcomes for 2788 patients with transthyretin amyloidosis: tafamidis meglumine early access program in France","volume":"118","author":"Lairez","year":"2025","journal-title":"Arch Cardiovasc Dis"},{"issue":"Suppl 1","key":"10.1016\/j.acvd.2025.11.014_bib0165","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1097\/WCO.0000000000000288","article-title":"Sixty years of transthyretin familial amyloid polyneuropathy (TTR-FAP) in Europe: where are we now? A European network approach to defining the epidemiology and management patterns for TTR-FAP","volume":"29","author":"Parman","year":"2016","journal-title":"Curr Opin Neurol"}],"container-title":["Archives of Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1875213626000318?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1875213626000318?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T23:47:41Z","timestamp":1782863261000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1875213626000318"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":33,"journal-issue":{"issue":"6-7","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S1875213626000318"],"URL":"https:\/\/doi.org\/10.1016\/j.acvd.2025.11.014","relation":{},"ISSN":["1875-2136"],"issn-type":[{"value":"1875-2136","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of RNAi therapeutics on cardiac parameters in patients with hereditary transthyretin amyloidosis initially treated with stabilizers: A French real-world study","name":"articletitle","label":"Article Title"},{"value":"Archives of Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.acvd.2025.11.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}